Altimmune Insider Buying Surge: CEO‑Elect and Other Executives Pump Shares Amid FDA Breakthrough Designation for Pemvidutide
Altimmune insider buying surges as CEO‑elect Pisano Wayne buys 5,000 shares near a 52‑week low, backing the company’s FDA Breakthrough Therapy designation and promising clinical‑stage growth.
2 minutes to read